Inogen (NASDAQ:INGN – Get Free Report) and OPKO Health (NASDAQ:OPK – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Valuation & Earnings
This table compares Inogen and OPKO Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inogen | $348.67 million | 0.46 | -$22.75 million | ($0.91) | -6.57 |
| OPKO Health | $606.90 million | 1.82 | -$225.68 million | ($0.27) | -5.41 |
Risk and Volatility
Inogen has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and target prices for Inogen and OPKO Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inogen | 1 | 0 | 1 | 1 | 2.67 |
| OPKO Health | 1 | 4 | 0 | 1 | 2.17 |
Inogen currently has a consensus target price of $14.00, suggesting a potential upside of 134.11%. OPKO Health has a consensus target price of $1.55, suggesting a potential upside of 6.16%. Given Inogen’s stronger consensus rating and higher probable upside, analysts clearly believe Inogen is more favorable than OPKO Health.
Profitability
This table compares Inogen and OPKO Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inogen | -7.08% | -12.90% | -8.27% |
| OPKO Health | -36.63% | -16.78% | -10.98% |
Insider & Institutional Ownership
89.9% of Inogen shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 2.5% of Inogen shares are owned by insiders. Comparatively, 49.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Inogen beats OPKO Health on 9 of the 14 factors compared between the two stocks.
About Inogen
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
About OPKO Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.
